The pentose phosphate pathway is a branch of the glycolytic pathway that not only produces ribonucleotides but is also a major source of NADPH. The pentose phosphate pathway consists of an oxidative branch that produces NADPH and ribonucleotides and a non-oxidative branch that recruits intermediate metabolites of glycolysis. Numerous studies have demonstrated that cancer directly or indirectly modulates the flux of the pentose phosphate pathway, thereby affecting the flux of glucose in glycolysis, the tumor microenvironment, and the proliferation of cancer cells. Therefore, studying the pentose phosphate pathway is crucial for a comprehensive understanding of cancer glucose metabolism, and can bring new hope for cancer treatment.
CD BioGlyco can provide based on the MOPCGM platform comprehensive analysis services of glucose metabolism in the cancer pentose phosphate pathway, including quantitative analysis of metabolites in the pentose phosphate pathway, expression of metabolism-related enzymes, and mutation of metabolism-related genes.
The level of the PPP in cancer cells is significantly increased, and targeting the PPP to treat cancer has become a director of tumor therapy. We can analyze the gene mutation of the PPP in cancer cells through genomics technology, explore the role of gene mutation in the PPP and its function in cancer progression, and find out what can be used as diagnostic markers, prognostic markers, and therapeutic targets PPP-related genes.
We can provide detection services for metabolites in the PPP based on metabolomics technology, including quantitative detection of intermediate metabolites in the PPP, and assessment of metabolic levels in the PPP.
Cancer cells primarily use glucose as a nutrient. After glucose enters cells, it is phosphorylated by hexokinase to generate glucose 6 phosphates, which can enter the glycolysis pathway and the PPP. Therefore, studying the glucose metabolic flux of the PPP is crucial for a comprehensive understanding of cancer glucose metabolism. We provide metabolic communication analysis of the PPP based on metabolic fluxomics technology.
The PPP is regulated by multiple enzymes. Proteomic studies have found that protein lysine residues undergo various post-translational acylation modifications, and post-translational modifications of key enzymes in the PPP are involved in the reprogramming of cancer glucose metabolism. We provide quantitative analysis of enzymes related to the PPP, analysis of post-translational modifications, and analysis of their regulation on the PPP based on proteomics technology.
CD BioGlyco provides analysis services specifically for glucose metabolism in the PPP, including PPP-related gene mutation analysis, quantitative detection services for metabolites, enzyme expression, activity analysis, post-translational modification analysis services, and metabolic flux analysis services. Our experienced teams of scientists, researchers, and technicians provide fast turnaround, high-quality services at competitive prices for worldwide customers. Our customers have direct access to our staff and prompt feedback on their inquiries. If you are interested in our services, please contact us for more details.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.